Sarika Jain, MD

This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.

Here, we provide an in-depth review of the current evidence for the addition of ovarian suppression to adjuvant endocrine therapy, and we offer recommendations for clinical management.